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Background: Chagas disease is caused by Trypanosoma cruzi, and humans acquire the parasite by exposure to
contaminated feces from hematophagous insect vectors known as triatomines. Triatoma virus (TrV) is the sole viral
pathogen of triatomines, and is transmitted among insects through the fecal-oral route and, as it happens with
T. cruzi, the infected insects release the virus when defecating during or after blood uptake.
Methods: In this work, we analysed the occurrence of anti-TrV antibodies in human sera from Chagas disease
endemic and non-endemic countries, and developed a mathematical model to estimate the transmission probability
of TrV from insects to man, which ranged between 0.00053 and 0.0015.
Results: Our results confirm that people with Chagas disease living in Bolivia, Argentina and Mexico have been exposed
to TrV, and that TrV is unable to replicate in human hosts.
Conclusions: We presented the first experimental evidence of antibodies against TrV structural proteins in human sera.
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Chagas disease is an arthropod-borne zoonotic disease
also known as American trypanosomiasis, and caused by
the protozoan flagellate parasite Trypanosoma cruzi [1].
This disease is endemic in most of the Latin American
countries, and between 7 to 8 million have been esti-
mated to be infected people in the American continent
[2]. T. cruzi is transmitted to humans and to wild and
domestic animals by many species of haematophagous
insects known as triatomines (Hemiptera: Reduviidae)
[1]. The most common source of infection is when the
parasite reaches the bloodstream of the bitten person
who scratches the bite site and contaminates the skin
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unless otherwise stated.The parasite can also infect the host through the
surfaces of mucosa and/or conjunctiva. In contrast to
salivarian pathogens such as Plasmodium spp., Leishmania
spp., and dengue virus, in which transmission to humans
occurs with 1 to 4 insect bites, the probability of being
infected with T. cruzi, a stercorarian parasite, is much
smaller: between 900 and 4,000 bites by an infected tria-
tomine are needed for T. cruzi infection to occur [3,4].
Triatoma virus (TrV) (Dicistroviridae: Cripavirus) is a
non-enveloped virus [5] and its genome contains two
open reading frames (ORFs). ORF1 (5,387 nt in length)
is responsible for encoding non-structural proteins such as
RNA helicase, cysteine protease (3C) and RNA-dependent
RNA polymerase (RdRp), while ORF2 (2,606 nt in length)
encodes the structural proteins VP1, VP2, VP3, and the
minor protein VP4 [6]. The precursor protein of VP2
and VP4 is known as VP0. This virus was first isolated
from Triatoma infestans [7,8], the main vector of Chagas
in Argentina and neighbouring countries. The area ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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along the Andes, the central part of the country and
also the region known as Gran Chaco; the latter is a
vast flat area (approximately one million km2) that
extends through northern Argentina, south-eastern
Bolivia, north-western Paraguay, and a small area of
south-western Brazil.
The virus replicates in the cells of the intestinal epithe-
lium of triatomines, and the viral infection causes leg
paralysis, delayed development, reduced fertility, and
mortality [7-9]. Previous studies described the mecha-
nisms of TrV transmission among triatomines and
found that it can occur through the fecal-oral route,
cannibalism, or transovarian infection [10]. In addition
to T. infestans, others species of triatomines from wild
areas in Argentina [11] and from an insectary in Brazil
were found to be infected with TrV [12]. This suggests
that TrV can be distributed to other areas of the American
continent.
To date, TrV is the only known viral pathogen of triato-
minesa. Recent studies have established TrV prevalence in
sylvatic populations of triatomines in the north-western
provinces of Argentina and determined that it can reach
up to 20% [13]. The virus infects several triatomine species
living in allecotopes [11]. One of the salient results of
an extensive study by Marti and colleagues was that the
average prevalence of TrV in T. infestans was approxi-
mately 9.7% [13], many times greater than the average
prevalence of other parasites, pathogens, and symbionts
found in the same sample of triatomines, and in particu-
lar of T. cruzi, which was found in approximately 1.3%
of the examined specimens.
It has been considered that millions of people, as well
as wild and domestic animals living in Chagas disease
endemic areas, may have been in contact with TrV [10].
This assumption has been supported by the observation
that hens used to feed triatomines infected with TrV,
had positive serology for anti-TrV antibodies [10], sug-
gesting that, similarly to what happens with T. cruzi,
humans or animals can be inoculated with TrV particles
existing in the feces of triatomines.
In this study, we searched for anti-TrV antibodies in
human sera of people living in both countries where
Chagas disease is endemic and non-endemic. Also, we
developed a mathematical model to estimate human
exposure to TrV, and compared the transmission rate of
TrV relative to that of T. cruzi.
Methods
Study population
In this work, we searched for anti-TrV antibodies in 410
human sera samples from four endemic and two non-
endemic Chagas disease countries (Table 1). We used
117 sera samples from Bolivia, 100 samples from Mexico,122 samples from Argentina, 50 samples from Brazil, 10
samples from Cuba and 11 samples from Portugal. Aside
from the samples used as controls, 62% of the sera sam-
ples came from patients with Chagas disease. This was to
guarantee that most of the patients had been in contact
with triatomines and consequently had an increased likeli-
hood of exposure to TrV.
In general, for each country and for all serological
assays, we analysed, as negative controls, sera from
healthy people with the same region. In particular, for
the controls of Argentina, healthy people sera came
from a TrV-free province. In the cases of Cuba and
Portugal (the non-endemic Chagas disease countries),
we used sera from people who had never been in coun-
tries endemic for Chagas disease.
Ethics statement
Sera samples were obtained and analyzed in accord-
ance with the institutional Ethics Committees regu-
lations from the countries where they were analysed.
Authorizations of ethics committees were obtained
individually in each country presented in the study:
Mexico (Faculty of Medicine – Universidad Autonoma de
Mexico - FMED/CI/RGG/024/08/2006 project # 035–
2009); Argentina (Institutional Bioethics Committee –
Bahia Blanca – Doc # 017/2010 from 17 October 2013);
Portugal (Institutional Bioethics Committee at Instituto de
Higiene e Medicina Tropical – Universidade Nova de
Lisboa); Brazil (Institutional Bioethics Committee at
Hospital São Salvador – Goiânia – GO); Bolivia (Institu-
tional Bioethics Committee at Faculty of Medicine – Uni-
versidad Mayor de San Simon); Cuba (consent of the ethics
and biosafety committee at CENPALAB).
ELISA specific for the detection of antibodies anti-Triatoma
virus structural proteins
Natural empty TrV particles (e-TrV) purified from the
feces of infected insects [14] were used as antigens. For
the total anti-TrV IgG in human sera determination,
e-TrV particles (100 ng/well) were diluted in 0.1 M
bicarbonate buffer (pH 8.5) and incubated overnight at
4°C in 96-well micro-plates (Nunc, Denmark). In this
indirect enzyme-linked immunosorbent assay (ELISA),
we used the human sera at a dilution of 1:10,000. Anti-
human IgG (whole molecule) −HRP antibody produced
in rabbit (1:4000, Sigma-Aldrich, USA) was used as a
secondary antibody and bound antibody was detected
by incubation with o-Phenylenediaminedihydrochloride
(Sigma-Aldrich, USA) and water (Sigma-Aldrich, USA) for
30 min. The reaction was stopped with 2MH2SO4, and
then the absorbance or Optical Density (OD) was read at
490 nm (Bio-Rad Microplate Reader 680 XR, USA). Data
from the ELISA assays were processed and analysed by
GraphPad Prism 6® (GraphPad Software; USA).
Table 1 Positive and negative sera for Triatoma virus by country of origin resulting from different types of analysis
Country Sera analysed Chagas patients (%) ELISA 1 positive ELISA 2 negative WB positive RT-PCR negative Negative control
Argentina 122 40 41 50 36 50 12
Bolivia 117 68 11 - - - 20
Brazil 50 100 0 - - - 22
Cuba 10 0* 0 - - - 5
Mexico 100 70 9 - - - 8
Portugal 11 100# 0 - - - 8
Total 410 63 61 50 36 50 81
Column 1 identifies the country of origin for the samples; results of the TrV sera analyses. Numbers in columns 4–7 indicate the number of serum samples employed in
each analysis. ELISA assay 1 corresponds to reactivity against structural proteins, and ELISA assay 2 corresponds to reactivity against the non-structural protein RdRp. WB
refers to immunoblotting analysis against the structural proteins of TrV. RT-PCR refers to reverse transcriptase-PCR*. Cuba is a non-endemic country for Chagas disease.
#The sera from Portugal are imported case of Chagas disease, mainly from Brazil.
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virus non-structural protein (RdRp)
We used the non-structural protein RdRp from TrV
as antigen. The protein was obtained by recombinant
expression in E. coli (see below). The procedure was the
same as described for ELISA assay 1, except that we
used an antibody dilution of 1:5,000. Each serum sample
was diluted in the antibody buffer and incubated over-
night with 6 μg of total E. coli proteins. This reduced the
background due to the occurrence of natural anti-E. coli
antibodies in human sera.
In both ELISAs, the cut-off values were obtained by
using negative control samples (see study population
above), by establishing the cut-off value as the mean of
the ODs plus three times the standard deviation, which
allowed us to discriminate between the negative and
positive sera.
Molecular identification of Triatoma virus by Reverse
Transcriptase-PCR (RT-PCR)
For molecular identification of TrV, we performed RNA
extraction and purification using TRIzol® Reagent (Life
TechnologiesTM, USA) of all positive sera (n = 41) and
some indeterminate sera (n = 9) from Argentina (previ-
ously analysed by ELISA assay 1). This subgroup of sera
will be referred hereafter as SeraA+. As a positive con-
trol, we used RNA extracted from TrV that was diluted
in sera from Portuguese patients who had never been in
Chagas disease endemic areas.
The RT-PCR was performed according to the literature
[15,16] using the following primer pair: TrV sense −5′
TCAAAACTAACTATCATTCTGG 3′(nt 7427 to 7448
in TrV ORF2 sequence) and TrV anti-sense - 5′TTCAGC
CTTATTCCCCCCC ′3 (nt 8240–8258), with an expected
product of 832 bp.
Expression and purification of the recombinant Triatoma
virus non-structural protein RdRp
ORF1 encodes for the non-structural protein precursor
NS, which contains the functional proteins helicase,protease, and RdRp. The cDNA fragment corresponding
to a domain containing a piece of RdRp (nucleotides
4275–5936) was obtained by RT-PCR using the following
primers: sense 5′-CATGCCATGGGAGGAGTTAGTCA
ACTACC-3′ (NcoI restriction site in italics) and antisense
5′-CCGCTCGAGCATAGTCAAGTCCGTAGGATTCC-3′
(XhoI restriction site in italics). The cDNA was then
inserted into a pET-28a vector (Novagen, Germany).
Bacteria were grown in Luria-Bertani liquid medium
with 0.025 mg/ml kanamycin at 37°C to A600 = 0.6-0.8.
Then, 1 mM IPTG was added for induction, and expres-
sion proceeded for 3 h at 37°C. Cells were harvested by
centrifugation (6,000 g, 10 min, 4°C).
The cell pellets were resuspended in lysis buffer
(500 mM NaCl, 20 mM Tris, pH 8.0) and were lysed by
sonication (25 cycles, 10 s on + 20 s off ) in a Soniprep
150 MSE probe sonicator. The suspensions were then
centrifuged at 30,000 g for 20 min at 4°C, and the inclu-
sion bodies, recovered in the pellet, were washed three
times using wash buffer (2 M urea, 500 mM NaCl, 1%
(v/v) Triton X-100, 20 mM Tris, pH 8.0). Finally, the
pellets were washed twice with PBS to remove Triton
X-100 and urea completely. To confirm protein expres-
sion, the samples were tested by SDS-PAGE and by
anti-His tag Western blot.
To isolate the recombinant RdRp protein from the
E. coli proteins, we performed protein purification from
polyacrylamide gels by sonication extraction [17].
Animal model mimicking Triatoma virus infection and
polyclonal anti-Triatoma virus antibody production in mice
Sera of mice inoculated with TrV were used as a positive
control for antigenic analyses. These positive sera were
produced in female Mus musculus BALB/c mice be-
tween 5 and 8 weeks of age, obtained from the Instituto
de Higiene e Medicina Tropical, Lisbon, Portugal. A
group of five mice were inoculated (intraperitoneal in-
jection) with 3 μg of TrV. Thirty days after inoculation,
the animals were anaesthetized to proceed the blood
collection through the cardiac puncture, and hyper-immune
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our previous study [18].
A group of five mice were used to produce polyclonal
anti-RdRp antibodies. The mice were inoculated with
100 μg of recombinant RdRp mixed with 100 μl of Freund’s
complete adjuvant (Sigma-Aldrich, USA). Fifty days after
the first inoculation, the animals were inoculated with
100 μg of recombinant RdRp mixed with 100 μl of Freund’s
incomplete adjuvant (Sigma-Aldrich, USA), and ten days
after the second inoculation, the animals were sacri-
ficed and hyper-immune sera were obtained using the
same procedure described in the previous paragraph.
Ethics statement
Animal experimentation was performed in accordance
with existing legislation in Portugal (Decreto-Lei number
113/2013) and in accordance with European directive
(Directive - 2010/63/EU).
Immunoblotting analysis
Empty-TrV particles (5 μg/well) were loaded onto 12%
polyacrylamide SDS-PAGE gels after denaturation at 95°C
for 5 min with β-mercaptoethanol. After running at 100 V,
the gel was equilibrated in a transfer buffer (192 mM
glycine, 20% methanol, 25 mM Tris pH 9.0) for 20 min.
Proteins were transferred from the gel to nitrocellulose
membranes using a semi-dry trans-blot system at 15 V
for 40 min. After the transference, membranes were
washed with PBS and blocked by incubation for 1 hour
with 3% BSA in PBS. In the Western blot analyses, the
sera were analysed at a dilution of 1:1,000. Rabbit anti-
human IgG (whole molecule) −HRP antibody (1:4,000,
Sigma-Aldrich, USA) was used as a secondary antibody
and bound antibody was detected by incubation with
3,3′-diaminobenzidine substrate (Sigma, USA). As a
negative control, we used the same group of sera from
Argentina that was used in the ELISA assays (see
above). By analogy to the reaction observed in mice (see
Results and Discussion), in this study we considered
that human sera reacting with three or four structural
proteins were positive cases of exposure to TrV.
Mathematical model to estimate Triatoma virus
transmission rate
The number of potential infective contactsb to which a
susceptible person is exposed is one of the main factors
in the transmission of a pathogen and thus a dominant
factor in determining the prevalence of the disease pro-
duced by that pathogen. Provided that contact between
an infected vector and a susceptible host generates a
detectable effect (like replication of the parasite or an
immune response against it), we can construct a general
model based on the relationship between the prevalence
of the infection, the number of potential contacts betweenvector and host, and the probability of the pathogen trans-
mission. In the model developed below we assume that the
population size of humans and vectors, the prevalence of
the disease in humans, and the prevalence of the parasite in
the vectors, are all constants in time and age-independent.
Let 'T ' be the probability of transmission of a parasite
from an infected vector to a susceptible (healthy) host,
'a' the prevalence of the parasite in the vector's popula-
tion, and 'N' the total susceptible individuals in a given
human population.
After the first potentially infective contact, the number
of individuals infected with the parasite is C1, and given by:
C1 ¼ aTN ð1Þ
In a second contact, the number of new infected indi-
viduals is:
C2 ¼ aT N−C1ð Þ ¼ aT N−aTNð Þ
¼ aTN 1−aTð Þ ð2Þ
In a third contact:
C3 ¼ aT N−C1−C2ð Þ
¼ aT N−aTN−aTN 1−aTð Þð Þ
¼ aTN 1−aTð Þ2
ð3Þ
And at the bite number m:
Cm ¼ aT N−C1−C2−…−Cm−1ð Þ
¼ aTN 1−aTð Þm−1 ð4Þ
Summing up the number of new infected individuals
between the first to m contacts (Ctot), the total fraction
of infected individuals is:
Ctot=N ¼ 1=N
Xm
j¼1Cj ¼ aT
Xm
j¼1 1−aTð Þ
j−1 ð5Þ
Equation 5 represents the fraction of the population
that was infected after 'm' potentially infective contacts
with the vector, i.e., the prevalence.
Taking into account the property of geometric series:
a
1−x
¼
X∞
p¼0
axpwith xj j < 1 ð6Þ
Applying eq (6) to eq. 5 we arrive at the following
expressions (see Additional file 1 for demonstration):
m ¼ ln 1−Pmð Þ
ln 1−aÄnT
  ð7Þ
T ¼ 1
a
1−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−Pm
m
p
Þ

ð8Þ
Being Pm the prevalence after m potentially infective
contacts, i.e., Pm =Ctot/N.
Figure 1 ELISA assay 1 analysis of human sera. The results of the
IgG antibodies against TrV structural proteins were analysed at an
absorbance of 490 nm. The cut-off value was the mean of the optical
density (OD) plus three times the standard deviation, so sera samples
with OD/cut-off values greater than 1.1 were considered positive; sera
samples with OD/cut-off values 0.9 < OD/cut-off < 1.1 were considered
indeterminate, and sera samples with values of OD/cut-off < 0.9 were
considered negative.
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In Chagas disease endemic areas, and considering only
vectorial, transmission, the prevalence of the disease is
directly related to the degree of vector exposure, which
can be expressed as number of potentially infective bites.
We can apply the mathematical model derived above to
estimate the number of bites per person (m) affecting a
population. To do so, the necessary data are the sero-
logical prevalence of T. cruzi (Ctot/N), the T. cruzi preva-
lence in the insects (aTc), and the probability of parasite
transmission to humans by an infected triatomine (TTc).
The values of Ctot/N and aTc can vary widely from one
geographical point to another, and the literature contains
abundant data for these two values that were obtained in
specific locations. We used the value measured in
Chaco, Argentina, with Ctot/N = 27.81% and aTc = 0.301
[19]. The parameter TTc cannot be measured directly
and depends on many factors, such as the triatomine
species involved, the insect density, prevalence in the
vector, etc. We used from the bibliography the TTc
values estimated for T. infestans in Argentina: 0.000202
[4] and 0.00058 [3], and applied them in equation 7
(as T = TTc) to estimate the number of bites or contacts
between humans and triatomines in Chaco, Argentina.Estimation of Triatoma virus transmission to humans
If TrV enters the bloodstream of a susceptible host, the
immune system will produce a response that can be de-
tected by different assays, and allow distinguishing
people who have been in contact with the virus from
people who have not. Under these assumptions eq 8 can
be used to compute the probability of TrV transmission
(TTrV) to humans. TrV prevalence in insects (aTrV) can
also be estimated. Given those pieces of data it is possible
to estimate the number of bites (m) from eq. 7, and
estimate the probability TTrV. The prevalence of TrV
was based on the average value estimated in Chaco’s
neighbouring provinces of Santa Fe and Santiago del
Estero [13], resulting in aTrV = 0.127.Results and discussion
Antibodies against structural proteins of Triatoma virus
The samples obtained from Brazil, Cuba and Portugal
displayed relatively weak serological reactivity, which
suggests that people might have never been exposed to
TrV (Figure 1, Table 1). Sera from Cuba were obtained
from people with no history of Chagas disease, so the
results are consistent, since the probability of these people
having been in contact with triatomines or TrV are too
low. On the other hand, the sera from Portugal are
imported case of Chagas disease, mainly from Brazil. So,
the results from Portugal and Brazil are very consistent,
since to date TrV was found in only one insectary fromBrazil, which may indicate the low prevalence of this virus
in natural population of triatomines from Brazil.
33.6% (n = 41) of sera analysed from Argentina, 9.4%
(n = 11) from Bolivia and 9% (n = 9) from Mexico
showed high levels of anti-TrV antibodies (Figure 1),
suggesting that individuals from those countries had
been exposed to this virus (Table 1). From the positive
Argentinean sera samples, five (12.2%) corresponded to
healthy individuals and the rest to Chagas patients. All
positive TrV sera samples from Bolivia and from Mexico
corresponded to patients with Chagas disease.
Because the distribution of TrV is widespread in the
northern provinces of Argentina (Figure 2), it is not sur-
prising that sera from Bolivian patients were positive for
the virus.
We would have not expected people from Mexico to
have been in contact with TrV, but although there are
no reports of TrV in triatomines from North America,
the triatomine species Meccus longipennis from a Brazilian
insectary was positive for TrV, and the colony was origin-
ally from Mexico [12]. The occurrence of TrV positive
human sera samples from this country suggests that the
virus may have spread throughout the Americas.
Confirmation of exposure to Triatoma virus in inhabitants
from Argentina
When sera from mice inoculated with TrV were tested
by immunoblotting (WB) assays, three or four bands
were detected (data not shown). These bands corre-
sponded to VP0, VP3, VP1, and VP2. Therefore this
assay, if positive, can be used as confirmatory evidence
of contact with TrV.
Figure 2 Geographical distribution of TrV prevalence in
triatomines, and provinces of origin of the sera from Argentina.
TrV was found in a region that covers nine provinces (colored in
blue) [20]. Red currency signs (¤) identify the four provinces where
the 36 sera sample with three positive immunological reactions
against TrV to TrV: Chaco (Ch), Santa Fe (SF), Santiago del Estero (SE)
and Salta (S). The remaining provinces with negative sera for TrV (86)
were Buenos Aires (BA), Jujuy (J), and Tucumán (T). Yellow Cyrillic Ef
(ϕ) identifies provinces origin of sera analysed.
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mines from Argentina, it is likely that people in Chagas
endemic areas from this country might have been exposed
to the virus. From the immunoblotting analysis of the fifty
sera samples from Argentina identified as SeraA+, 36 sera
samples (72%) were positive to TrV (Figure 3, Table 1).
These 36 sera samples from Argentinean individuals canFigure 3 Immunoblotting analysis against the structural proteins of Triat
(e-TrV). Lines 1–8 show reactive sera of eight selected samples. Out of a total o
three or four VPs; Iinesnc1 and nc2 correspond to sera of individuals from Triatbe considered confirmed cases of exposure to TrV; of
those 36 cases five (13.9%) were negative to T. cruzi. Inter-
estingly, all these people inhabit provinces reported as
endemic for TrV [13] (Figure 2).
Triatoma virus is unable to replicate in human hosts
Viruses with a genome composed of -ssRNA and dsRNA
enclose their own RdRp within the viral capsid [21]. In
contrast to these viruses, TrV is a + ssRNA virus and
does not contain this polymerase within the viral capsid.
This implies that to have effective replication within a
host cell, TrV needs to promote the synthesis of all non-
structural and structural protein precursors. So, only in
case of active viral replication, the host immune system
can produce antibodies that recognize both the struc-
tural and non-structural viral proteins. When a reaction
to both groups of proteins is determined, this not only
indicates that the host was exposed to the virus but also
that the pathogen was able to replicate by expressing its
own proteins through the use of the host cell machinery.
On the contrary, if only antibodies against structural
proteins are found, this implies that exposure to the
virus was passive [22].
To differentiate passive exposure to TrV from active
viral replication, we analysed the subgroup SeraA+ sam-
ples by an ELISA against recombinant RdRp from TrV
(ELISA assay 2). Our results showed that there was no
serological reactivity against recombinant RdRp from
TrV (Figure 4, Table 1).
Reverse Transcriptase-PCR (RT-PCR) is widely used in
molecular diagnosis of RNA viruses. In this study, we
used RT-PCR for molecular diagnosis of TrV in the
SeraA+ subgroup samples, and there were no positiveoma virus. Each strip was loaded with 5 μg of capsid protein from TrV
f 50 analysed samples, 36 resulted positive, i.e., showed reactivity against
oma virus-free provinces of Argentina.
Figure 4 ELISA assay 2 analyses against RdRp of TrV. RdRp is a
non-structural protein of TrV, and negativity to this protein indicates
that the virus does not replicate in the infected host. Sera samples
with a ratio of OD/cut-off smaller than 1.1 were considered negative.
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ELISA assay 2, indicate that TrV is unable to replicate in
the human host, as it was observed in sera samples from
mice experimentally inoculated with TrV [18].The probability of Triatoma virus transmission to humans
is greater than that of Trypanosoma cruzi
The calculation of human T. cruzi prevalence for Chaco,
Argentina, using the mathematical model under the
assumption of a prevalence of T. cruzi in triatomines of
aTc = 0.301 [19], and as a function of various numbers of
potentially infective contacts, are shown in Figure 6, forFigure 5 Molecular diagnosis of TrV in human sera by RT-PCR.
Lane 1: human sera from a non-endemic country; Lane 2: Pool of
negative sera used in immunochemical assays (Western blot); Lane 3:
Pool of positive sera analysed by immunochemical assays (Western blot);
Lane 4: 5 μl of pure TrV diluted in serum; Lane 5: 5 μl of pure TrV
diluted in water.two values for the T. cruzi transmission rate (T1Tc =
0.00053, and T2Tc = 0.000202) [3,4]. Using eq. 7, and the
T. cruzi field prevalence value of 27.81% for that region,
we estimated the number of potentially infective bites
that people would have been exposed to: 1,886 (= m1)
and 5,359 (= m2), for the two TTc values used; these two
estimates are also shown in Figure 6. Thus, using eq. 8 the
two transmission probabilities of TrV to humans are
T1TrV =0.001709 for m =m1, and T
2TrV = 0.0006016 for
m =m2. Both results indicate that the probability of
TrV transmission to humans is about three times greater
than the transmission rate of T. cruzi to humans (T1TrV
/T1Tc = 3.22 and T2TrV /T2Tc = 2.97). This estimation, of
course, is specifically for the population of Chaco and
cannot be generalized to other regions.
As the sera samples were randomly selected, they
should be representative of the true prevalence of people
seropositive to TrV. This value is approximately 30%,
whereas the average prevalence of the virus in triatomines
is approximately 10%; this relationship, and the surpris-
ingly high percentage of people positive to TrV we found
in Argentina has to be explained. One possibility is the
possible difference in the mechanism of entrance to the
human bloodstream between TrV T. cruzi. Although both
pathogens infect by ingestion of contaminated food or by
contaminated feces entering a skin wound or the conjunc-
tiva, T. cruzi is destroyed in dry triatomine feces and high
temperatures [23], while TrV can remain viable at room
temperature for many months or years in dry triatomine
feces [14]. This resistance to adverse climatic conditions
(high ambient temperature and low relative humidity)
could be a factor to increase its transmission probability
to humans. For instance, human contact with TrV may
occur by breathing of infected feces dust (Additional file 2:
Figure S1), although the confirmation of this route of
infection remains to be shown.
Our estimation of the transmission rate of TrV from
an infected vector to a susceptible human host is based
on the assumption that in an individual insect the
co-infection of T. cruzi and TrV is possible; however, an
evaluation of this possibility has never been investigated,
and goes beyond the goal of this work; as it is a critical
hypothesis to the analysis of the transmission of both
TrV and T. cruzi, it justifies more research.
Conclusions
We presented the first experimental evidence of anti-
bodies against TrV structural proteins in human sera.
Because we aimed to analyse people more likely to have
viral exposure, and because TrV is released with insect
feces, the majority of the sera analysed in this study
came from Chagas disease patients. Our findings con-
trast with a previous study that failed to demonstrate
viral exposure in patients with Chagas disease from
Figure 6 Estimation of the number of potential infective contacts for Chagas patients in Chaco (Argentina). Predicted prevalence to T.
cruzi in humans computed from our mathematical model of infection (eq. 5) using a T. cruzi prevalence value in triatomines of aTc = 0.301,from a
specific population of Chaco, Argentina [18]. Two values of the transmission rate parameter TTc = 0.000202 [4] and TTc = 0.00058 [3] were used.
From eq. 7 we calculated, for a given prevalence of T. cruzi in humans of 27.81% (from the same population of Chaco, Argentina [18]), the number of
potentially infective bites that the human population would be exposed to, resulting in 1,866 and 5,359 bites (magenta and blue curves, respectively).
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does not replicate in humans is in agreement with previ-
ous observations of other dicistroviruses that, in spite of
having been in contact with hens, horses, cows, rabbits
and sheep, did not replicate [22].
To date there is no effective vaccine for Chagas disease
prevention, so vector control has been the main mechan-
ism to decrease T. cruzi transmission [1]. Because know-
ledge of the biology of several members of the
Dicistroviridae family has increased, the possibility of using
viruses with RNA genomes as biological control agents for
insects looks promising [24]. Our results indicate that TrV
seems unable to replicate in human hosts, and this is con-
sistent with our recent observation that this virus is also
unable to replicate in mice [18]. These findings suggest
that TrV (and most likely all dicistroviruses) do not pose
any risk to humans nor wild and domestic animals, leaving
open the possibility of using this virus as biopesticide to
control the vectors of Chagas disease.
Endnotes
aPrevious studies have found virus-like particles in tria-
tomines from Brazil [20,25]. However, these particles were
extracted from insects showing no sign of disease and
were not further characterized aside from electron micros-
copy and RNA analysis. The estimated diameter of those
particles was 38-40 nm, larger than the 30 nm of TrV.
bAn ‘infective contact’ can be a bite of the insect
vector, ingestion of contaminated food, incorporation of
the parasite through the mucosa, etc.Additional files
Additional file 1: Analytical proof of eq. 7 and eq. 8 from eq. 5
using a geometric series approximation.
Additional file 2: Figure S1. T. infestans inhabits houses and domestic
animal shelters. The insect's “nests” are generally in cracks of the plastering or
between the joints of the roof with the walls. After feeding on their hosts,
the insects return back to their “nest” and defecate on their way. The
feces containing TrV are exposed to hot and dry air favoring ambient
contamination, resulting in a potential source of TrV particles. Picture
taken in a hen shelter in a rural area of Camiri, Bolivia (October 2012).
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